ClinicalTrials.gg
RecruitingNCT06963034Updated Mar 6, 2026

NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

A Phase 3 interventional study of NBI-1117568 and Placebo in Schizophrenia, sponsored by Neurocrine Biosciences. Recruiting at 21 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
284
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Schizophrenia by Neurocrine Biosciences — 6 open to participants now, 6 under way, 4 of them phase 3. Schizophrenia · Neurocrine Biosciences.

Planned enrollment
4th of 16
284 · median 165
Started
2025
with 4 others
Phase 3
6 of 16
4 open now
Registered
11th of 16
by date

Among the 16 studies in Schizophrenia by Neurocrine Biosciences, this one is the 4th largest by planned enrollment, is one of 5 that started in 2025, is one of 6 in phase 3, and was the 11th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 16 studies in Schizophrenia by Neurocrine Biosciences are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Schizophrenia by Neurocrine Biosciences, or all of them as a file.
02

Study summary

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant has a primary diagnosis of schizophrenia
  • Participant is experiencing an acute exacerbation or relapse of symptoms and currently warrants hospitalization.
  • Participants taking prohibited medications, including antipsychotics, must discontinue before study participation
  • Participant is willing and able to remain in an inpatient setting for the study duration, follow instructions, and comply with the protocol requirements

Key Exclusion Criteria:

  • Participant has known to any component of the formulation of NBI-1117568.
  • Participant has an unstable or poorly controlled medical condition or chronic disease
  • Participant is considered by the investigator to be at imminent risk of suicide or injury to self or others
  • Participant has a diagnosis of moderate or severe substance use disorder (with the exception of nicotine or caffeine dependence) within 6 months prior to screening
  • Participant has a positive alcohol test or drug screen for disallowed substances
  • Participants have a history of poor or suspected poor compliance in clinical research studies and/or in the investigator's opinion, the participant is not capable of adhering to the protocol requirements.

Note: Other protocol-specified inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
284 participants (estimated)

Study arms

  • Experimental
    NBI-1117568

    Participants will receive NBI-1117568 once daily (QD) orally from Day 1 to Day 35 for a total of 5 weeks.

    Drug: NBI-1117568

  • Placebo comparator
    Placebo

    Participants will receive matching placebo QD orally from Day 1 to Day 35 for a total of 5 weeks.

    Drug: Placebo

Interventions

  • NBI-1117568 will be administered per schedule specified in the arm description.

  • DrugPlacebo

    Placebo will be administered per schedule specified in the arm description.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5

    Time frame: Baseline, Week 5

Secondary outcomes

  1. Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 5

    Time frame: Baseline, Week 5

07

Study locations

21 of 21 sites recruiting
  • Neurocrine Clinical Site
    Bryant, Arkansas 72022, United States
    Recruiting
  • Neurocrine Clinical Site
    Little Rock, Arkansas 72211, United States
    Recruiting
  • Neurocrine Clinical Site
    Anaheim, California 92805, United States
    Recruiting
  • Neurocrine Clinical Site
    Pico Rivera, California 90660, United States
    Recruiting
  • Neurocrine Clinical Site
    San Diego, California 92123, United States
    Recruiting
  • Neurocrine Clinical Site
    Sherman Oaks, California 91403, United States
    Recruiting
  • Neurocrine Clinical Site
    Torrance, California 90504, United States
    Recruiting
  • Neurocrine Clinical Site
    Hollywood, Florida 33024, United States
    Recruiting
  • Neurocrine Clinical Site
    Miami Lakes, Florida 33016, United States
    Recruiting
  • Neurocrine Clinical Site
    Atlanta, Georgia 30331, United States
    Recruiting
  • Neurocrine Clinical Site
    Decatur, Georgia 30030, United States
    Recruiting
  • Neurocrine Clinical Site
    Snellville, Georgia 30078, United States
    Recruiting
  • Neurocrine Clinical Site
    Chicago, Illinois 60640, United States
    Recruiting
  • Neurocrine Clinical Site
    Gaithersburg, Maryland 20877, United States
    Recruiting
  • Neurocrine Clinical Site
    Watertown, Massachusetts 02472, United States
    Recruiting
  • Neurocrine Clinical Site
    Marlton, New Jersey 08053, United States
    Recruiting
  • Neurocrine Clinical Site
    Staten Island, New York 10314, United States
    Recruiting
  • Neurocrine Clinical Site
    The Bronx, New York 10461, United States
    Recruiting
  • Neurocrine Clinical Site
    Austin, Texas 78754, United States
    Recruiting
  • Neurocrine Clinical Site
    DeSoto, Texas 75115, United States
    Recruiting
  • Neurocrine Clinical Site
    Houston, Texas 77043, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Oct 2027, 29 months after the start.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's planned 29 months is close to that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
May 8, 2025
StartActual
May 8, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06963034
Responsible party
Sponsor
First posted
May 8, 2025
Start date
May 8, 2025
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Mar 6, 2026

Study contacts

Neurocrine Medical Information Call Center
Contact
medinfo@neurocrine.com
877-641-3461
Clinical Development Lead
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Direclidine

Start the discussion